454 related articles for article (PubMed ID: 31977852)
1. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study.
Wang Y; Hu X; Xu W; Wang H; Huang Y; Che G
Thorac Cancer; 2019 Jun; 10(6):1402-1411. PubMed ID: 31104359
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
[TBL] [Abstract][Full Text] [Related]
7. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
9. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma.
Yapar A; Tokgöz MA; Yapar D; Atalay İB; Ulucaköy C; Güngör BŞ
Jt Dis Relat Surg; 2021; 32(2):489-496. PubMed ID: 34145828
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
Zhang Y; Jiang C; Li J; Sun J; Qu X
Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M
PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
15. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
[TBL] [Abstract][Full Text] [Related]
17. Predictive values of the postoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio for the diagnosis of early periprosthetic joint infections: a preliminary study.
Zhao G; Chen J; Wang J; Wang S; Xia J; Wei Y; Wu J; Huang G; Chen F; Shi J; Lyu J; Liu C; Huang X
J Orthop Surg Res; 2020 Nov; 15(1):571. PubMed ID: 33256763
[TBL] [Abstract][Full Text] [Related]
18. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
[TBL] [Abstract][Full Text] [Related]
19. Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer.
Cheng H; Bhushan S; Li N; Xiao Z; Gao K
J Cancer Res Ther; 2022; 18(6):1666-1673. PubMed ID: 36412428
[TBL] [Abstract][Full Text] [Related]
20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]